A Phase 2 interventional study of Uprifosbuvir 450 mg and Ruzasvir 60 mg in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Hepatitis C, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · Merck & Co., Inc.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 28th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2016, is one of 16 in phase 2, and was the 110th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc is open now. The open studies under Hepatitis C, Chronic, anywhere →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 23 · Phase 3 34 · Phase 4 8
First in 2002; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 113 across the 72 interventional studies, 442 across the 35 observational. Of the 106 that completed or were terminated, 81 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection. The impact of the study treatment regimen on the percentage of participants with undetectable HCV ribonucleic acid [RNA] 12 weeks after completing study treatment (SVR12) will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
Drug: Uprifosbuvir 450 mg · Drug: Ruzasvir 60 mg
450 mg administered as 3 x 150 mg oral tablets
Also known as: MK-3682
60 mg administered as 6 x 10 mg oral capsules
Also known as: MK-8408
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)
The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma \< lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.
Time frame: Week 24 (12 weeks after completing study therapy)
Percentage of Participants With ≥1 Adverse Events (AEs)
The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)
Percentage of Participants Withdrawing From Study Therapy Due to an AE
The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to Week 12
Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)
The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>500 IU/L; 3) first instance of ALT or AST \>3x nadir and \>3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2; or 4) first instance of serum creatinine \>1.3x ULN and elevated from baseline.
Time frame: Up to Week 14 (up to 2 weeks after completing study therapy)
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)
The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.
Time frame: Week 36 (24 weeks after completing study therapy)
Percentage of Participants With Virologic Failure (VF)
The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA \< LLOQ while on treatment); 2) rebound (\>1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being \<LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection
Time frame: 12 weeks after the end of all study therapy (24 weeks)
Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12
The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.
Time frame: 12 weeks after the end of all study therapy (24 weeks)
Adult participants with hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, or 6 infection were enrolled at 5 study centers in the United States. Participants with HCV GT5 infection were initially intended for inclusion but none were enrolled.
| Milestone | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Started | 69 | 29 | 39 | 20 | 3 |
| Completed | 65 | 28 | 29 | 19 | 2 |
| Not completed | 4 | 1 | 10 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated prior to completion | 2 | 0 | 5 | 0 | 1 |
The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma \< lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.
| Percentage of Participants | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12) | 97.1 (89.9 to 99.6) | 100.0 (87.7 to 100.0) | 76.9 (60.7 to 88.9) | 90.0 (68.3 to 98.8) | 66.7 (9.4 to 99.2) |
The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of Participants | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Percentage of Participants With ≥1 Adverse Events (AEs) | 52.2 | 44.8 | 43.6 | 55.0 | 66.7 |
The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of Participants | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Percentage of Participants Withdrawing From Study Therapy Due to an AE | 0.0 | 3.4 | 0.0 | 5.0 | 0.0 |
The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.
| Percentage of Participants | GT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24) | 96.2 | 100.0 | 75.0 | 90.0 | 66.7 | 100.0 |
The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA \< LLOQ while on treatment); 2) rebound (\>1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being \<LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection
| Percentage of Participants | GT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Virologic Failure (VF) | 3.7 | 0.0 | 23.1 | 5.0 | 33.3 | 0.0 |
The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma \< LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.
| Percentage of Participants | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12 | 97.1 | 100.0 | 97.4 | 94.7 | 66.6 |
The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>500 IU/L; 3) first instance of ALT or AST \>3x nadir and \>3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2; or 4) first instance of serum creatinine \>1.3x ULN and elevated from baseline.
| Percentage of Participants | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Overdose | 4.3 | 3.4 | 5.1 | — | — |
| Non-overdose ECI | 2.8 | — | 2.5 | — | — |
Collected over Up to 36 weeks (up to 24 weeks after completing study treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | 0/69 (0%) | 4/69 (5.8%) | 25/69 (36.2%) |
| GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | 0/29 (0%) | 0/29 (0%) | 8/29 (27.6%) |
| GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | 1/39 (2.6%) | 1/39 (2.6%) | 13/39 (33.3%) |
| GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | 0/20 (0%) | 2/20 (10%) | 6/20 (30%) |
| GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Arthritis bacterialInfections and infestations | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| Staphylococcal bacteraemiaInfections and infestations | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| Urinary tract infectionInfections and infestations | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| SciaticaNervous system disorders | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 0/69 | 0/29 | 0/39 | 1/20 | 0/3 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/69 | 0/29 | 1/39 | 0/20 | 0/3 |
| MelaenaGastrointestinal disorders | 1/69 | 0/29 | 0/39 | 0/20 | 0/3 |
| Oesophagitis haemorrhagicGastrointestinal disorders | 1/69 | 0/29 | 0/39 | 0/20 | 0/3 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/69 | 0/29 | 0/39 | 0/20 | 0/3 |
| Event | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg |
|---|---|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 0/69 | 0/29 | 0/39 | 0/20 | 1/3 |
| FatigueGeneral disorders | 7/69 | 2/29 | 0/39 | 0/20 | 1/3 |
| Upper respiratory tract infectionInfections and infestations | 1/69 | 1/29 | 0/39 | 0/20 | 1/3 |
| Urinary tract infectionInfections and infestations | 3/69 | 1/29 | 1/39 | 1/20 | 1/3 |
| InsomniaPsychiatric disorders | 0/69 | 0/29 | 0/39 | 1/20 | 1/3 |
| NasopharyngitisInfections and infestations | 0/69 | 0/29 | 0/39 | 3/20 | 0/3 |
| HeadacheNervous system disorders | 3/69 | 3/29 | 1/39 | 1/20 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 4/69 | 0/29 | 4/39 | 1/20 | 0/3 |
| FlatulenceGastrointestinal disorders | 2/69 | 0/29 | 1/39 | 2/20 | 0/3 |
| NauseaGastrointestinal disorders | 6/69 | 1/29 | 3/39 | 2/20 | 0/3 |
| Age, Continuous(Years) | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 49.8 ± 10.7 | 57.2 ± 6.8 | 48.7 ± 10.3 | 56.5 ± 8.5 | 61.3 ± 1.5 | 51.9 ± 10.3 |
| Sex: Female, Male(Participants) | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | Total |
|---|---|---|---|---|---|---|
| Female | 33 | 10 | 18 | 5 | 1 | 67 |
| Male | 36 | 19 | 21 | 15 | 2 | 93 |
| Race (NIH/OMB)(Participants) | GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg | GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 0 | 1 | 0 | 7 |
| White | 64 | 27 | 39 | 19 | 0 | 149 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from May 2016 to primary completion in Jul 2017, 14 months.
Results were first posted in Aug 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Uprifosbuvir · Ruzasvir